相关实验视频
Updated: Aug 22, 2026

11:28
Analytical Techniques for Assaying Nitric Oxide Bioactivity
Published on: June 18, 2012
内皮氧化合成酶的重组基因转移在缺氧期间增加了冠状动脉放松
D G Cable1, V J Pompili, T O'Brien
1Cardiac Surgical Research Center, Section of Cardiovascular Surgery, Mayo Clinic and Mayo Foundation, Rochester, MN 55905, USA.
Circulation
|November 24, 1999
概括
氧化合成酶的基因转移增强了犬冠状动脉中缺氧诱导的放松. 这种方法可能有助于减少冠状动脉血管.
科学领域:
- 心血管生物学 心血管生物学
- 分子医学是分子医学.
- 基因治疗 基因治疗
背景情况:
- 冠状动脉表现出缺氧诱导的放松,由氧化 (NO) 介导.
- 增加氧化合成酶 (NOS) 表达可能会增强这些放松.
- 这项研究研究了内皮增强NOS (eNOS) 表达在缺氧期间对犬冠状动脉的影响.
研究的目的:
- 为了评估腺病毒介导的eNOS基因转移对犬冠状动脉中缺氧诱导的放松的影响.
- 为了确定是否增加eNOS表达可以改善低氧条件下的血管放松.
主要方法:
- 狗冠状动脉段经过腺病毒编码ENOS (Ad.CMVeNOS) 或病毒控制的治疗.
- 免疫组织化学证实了内皮细胞和前端细胞中eNOS的表达.
- 测量了缺氧诱导的短暂放松和对前列腺素F (2α) 的反应.
主要成果:
- 治疗Ad.CMVeNOS导致内皮和随机ENOS表达增加,cGMP水平增加了5倍.
- 动脉与增强的eNOS显示减少最大收缩到前列腺素F ((2alpha).
- 与对照组相比,Ad.CMVeNOS治疗的动脉中,低氧诱导的短暂放松显著增加 (45.2%与26.3-27.2%相比).
结论:
- 腺病毒介导的eNOS基因转移有效地减少了受体依赖的收缩,并增强了犬冠状动脉中缺氧诱导的放松.
- 通过基因转移增加NO的产量是缓解冠状动脉血管的潜在策略.
相关概念视频
Regulation of Angiogenesis and Blood Supply
Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits. Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl hydroxylase and factor...
Nitric Oxide Signaling Pathway
Nitric oxide (NO), an inorganic gas, acts as a potent second messenger in most animal and plant tissues. NO diffuses out of the cells that produce it and enters the neighboring cells to generate a downstream response. NO synthase (NOS) catalyzes NO production by the deamination of the amino acid arginine. There are three isoforms of NOS. Endothelial cells have endothelial NOS (eNOS), nerve and muscle cells have neuronal NOS (nNOS), and macrophages produce inducible NOS (iNOS) upon exposure to...
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...

